1. Show article details.

    BRIEF-Sellas Life Sciences Reports First Quarter 2022 Results

    Reuters – 4:47 PM ET 05/12/2022

    Sellas Life Sciences Group Inc (SLS): * SELLAS LIFE SCIENCES REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE. * Sellas Life Sciences Group Inc (SLS)- QTRLY LOSS PER SHARE $1.05 Source text for Eikon: Further company coverage:

  2. Show article details.

    SELLAS Life Sciences Reports First Quarter 2022 Financial Results and Provides Business Update

    GlobeNewswire – 4:12 PM ET 05/12/2022

    - Enhanced Pipeline with New Asset, GFH009, an In-licensed Next-Generation, Highly Selective CDK9 Inhibitor - - $25 Million of Gross Proceeds from Capital Raise in April 2022 and $1 Million Milestone Payment Received in May 2022 Add to Cash Balance of $14.3 Million as of March 31, 2022 - NEW YORK, May 12, 2022 -- SELLAS Life Sciences Group, Inc. (SLS), a late-stage clinical biopharmaceutical company ...

  3. Show article details.

    BRIEF-SELLAS Life Sciences Launches Expanded Access Program for Galinpepimut-S

    Reuters – 9:13 AM ET 04/26/2022

    Sellas Life Sciences Group Inc (SLS): * SELLAS LIFE SCIENCES LAUNCHES EXPANDED ACCESS PROGRAM FOR GALINPEPIMUT-S Source text for Eikon: Further company coverage:

  4. Show article details.

    SELLAS Life Sciences Launches Expanded Access Program for Galinpepimut-S

    GlobeNewswire – 8:30 AM ET 04/26/2022

    SELLAS Life Sciences Group, Inc. (SLS), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the Company has launched a Pre-Approval Access/Expanded Access Program with SELLAS’ lead asset, GPS, for treating patients suffering from acute myeloid leukemia.

  5. Show article details.

    Benzinga's Top Ratings Upgrades, Downgrades For April 14, 2022

    Benzinga – 10:03 AM ET 04/14/2022

    For United Parcel Service Inc, Loop Capital upgraded the previous rating of Hold to Buy. According to WestPark Capital, the prior rating for Paysafe Ltd was changed from Hold to Buy. Baird upgraded the previous rating for H.B. Fuller Co from Neutral to Outperform. Morgan Stanley upgraded the previous rating for International Business Machines Corp from Equal-Weight to Overweight.

  6. Show article details.

    BRIEF-Sellas Life Sciences' GFH009 Asset Shows Significant Anti-Leukemic Effect In Phase 1 Study

    Reuters – 10:56 AM ET 04/11/2022

    Sellas Life Sciences Group Inc (SLS): * SELLAS LIFE SCIENCES' NEWLY LICENSED GFH009 ASSET SHOWS SIGNIFICANT ANTI-LEUKEMIC EFFECT IN ACUTE MYELOID LEUKEMIA PATIENTS RELAPSED/REFRACTORY TO VENETOCLAX IN ONGOING PHASE 1 STUDY. * Sellas Life Sciences Group Inc (SLS) - FIFTH DOSE LEVEL COHORT OF GFH009, A HIGHLY SELECTIVE CDK9 INHIBITOR, INITIATED.

  7. Show article details.

    SELLAS Life Sciences’ Newly Licensed GFH009 Asset Shows Significant Anti-Leukemic Effect in Acute Myeloid Leukemia Patients Relapsed/Refractory to Venetoclax in Ongoing Phase 1 Study

    GlobeNewswire – 8:15 AM ET 04/11/2022

    - Fifth Dose Level Cohort of GFH009, a Highly Selective CDK9 Inhibitor, Initiated - - No Dose-Limiting Toxicities in First Four Dose Levels - SELLAS Life Sciences Group, Inc. (SLS), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the first acute myeloid leukemia patient has enrolled in the fift...

  8. Show article details.

    The Daily Biotech Pulse: BioXcel's Igalmi Gets FDA Nod, Citius Spikes On Positive Phase 3 Data, Iovance Receives Positive Regulatory Feedback For Skin Cancer Therapy

    Benzinga – 8:02 AM ET 04/06/2022

    Here's a roundup of top developments in the biotech space over the last 24 hours. Iovance Biotherapeutics, Inc. said the U.S. Food and Drug Administration on Friday provided a positive feedback regarding its proposed matrix of potency assays for its upcoming biologics license application for lifileucel in metastatic melanoma.

  9. Show article details.

    BRIEF-Sellas Life Sciences Announces Achievement Of Development Milestone For Approval Of IND For Galinpepimut-S In China

    Reuters – 7:09 AM ET 04/06/2022

    Sellas Life Sciences Group Inc (SLS): * SELLAS LIFE SCIENCES ANNOUNCES ACHIEVEMENT OF DEVELOPMENT MILESTONE FOR APPROVAL OF IND FOR GALINPEPIMUT-S IN CHINA Source text for Eikon: Further company coverage:

  10. Show article details.

    SELLAS Life Sciences Announces Achievement of Development Milestone for Approval of IND for Galinpepimut-S in China

    GlobeNewswire – 7:00 AM ET 04/06/2022

    SELLAS Life Sciences Group, Inc. (SLS), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that an Investigational New Drug application to initiate the first clinical trial in China for 3D189, also known as SELLAS’ galinpepimut-S, has been approved by China’s National Medical Products Administration.

  11. Show article details.

    SELLAS Life Sciences Provides Business Update and First Quarter 2022 Highlights

    GlobeNewswire – 4:51 PM ET 04/05/2022

    – In-licensed Next-Generation, Highly Selective CDK9 Inhibitor – – Closed Underwritten Public Offering with Gross Proceeds of $25 Million – – Appointed Robert Francomano as Chief Commercial Officer – – Completed Enrollment in Phase 1/2 Study of Galinpepimut-S in Combination with Merck’s KEYTRUDA® – – IND Application in China for Phase I Study of GPS Approved by China’s NMPA – – Shareholder Upda...

  12. Show article details.

    55 Biggest Movers From Friday

    Benzinga – 4:59 AM ET 04/04/2022

  13. Show article details.

    Mid-Afternoon Market Update: Nasdaq Turns Lower; Chicken Soup for the Soul Entertainment Shares Spike Higher

    Benzinga – 3:16 PM ET 04/01/2022

    U.S. stocks pared gains, with the Nasdaq Composite turning lower toward the end of trading on Friday. The Dow traded up 0.16% to 34,732.60 while the NASDAQ fell 0.15% to 14,199.63. The S&P also fell, dropping, 0.01% to 4,529.95. Also check this: Alphabet And 3 Other Stocks Sold By Insiders Leading and Lagging Sectors Real estate shares jumped by 1.6% on Friday.

  14. Show article details.

    Mid-Day Market Update: Gold Drops Over 1%; Manning & Napier Shares Jump

    Benzinga – 12:57 PM ET 04/01/2022

    U.S. stocks traded slightly higher midway through trading following the release of non-farm payroll data for March. The Dow traded up 0.06% to 34,698.84 while the NASDAQ rose 0.34% to 14,269.29. The S&P also rose, gaining, 0.11% to 4,535.50. Also check this: Alphabet And 3 Other Stocks Sold By Insiders Leading and Lagging Sectors Energy shares jumped by 1.1% on Friday.

  15. Show article details.

    38 Stocks Moving In Friday's Mid-Day Session

    Benzinga – 12:56 PM ET 04/01/2022

    38 Stocks Moving In Friday's Mid-Day Session

  16. Show article details.

    Mid-Morning Market Update: Markets Higher; US Economy Adds 431,000 Jobs In March

    Benzinga – 10:21 AM ET 04/01/2022

    U.S. stocks opened higher this morning following the release of non-farm payroll data for March. The Dow traded up 0.17% to 34,735.64 while the NASDAQ rose 0.30% to 14,262.94. The S&P also rose, gaining, 0.20% to 4,539.56. Also check this: Alphabet And 3 Other Stocks Sold By Insiders Leading and Lagging Sectors Energy shares jumped by 1.1% on Friday.

  17. Show article details.

    The Daily Biotech Pulse: SELLA In-licenses Oncology Asset, Merck's Pneumococcal Vaccine Review Extended, Arc Biopharma COVID Drug Flunks Mid-Stage Study

    Benzinga – 9:08 AM ET 04/01/2022

    Here's a roundup of top developments in the biotech space over the last 24 hours. Reata Pharmaceuticals, Inc. said it has completed filing the rolling submission of a new drug application to the U.S. Food and Drug Administration for omaveloxolone for the treatment of patients with Friedreich's ataxia.

  18. Show article details.

    SELLAS Life Sciences Stock Plunges After $25M Capital Raise Via Equity, In-Licenses Cancer-Focused CDK9 Inhibitor

    Benzinga – 8:41 AM ET 04/01/2022

    GenFleet Therapeutics has granted GFH009 rights to SELLAS Life Sciences Group Inc  across all therapeutic and diagnostic uses worldwide outside of Greater China. 

  19. Show article details.

    BRIEF-Sellas Life Sciences Says Pricing Of $25 Mln Underwritten Public Offering

    Reuters – 9:06 PM ET 03/31/2022

    Sellas Life Sciences Group Inc (SLS): * SELLAS LIFE SCIENCES ANNOUNCES PRICING OF $25.0 MILLION UNDERWRITTEN PUBLIC OFFERING. * SELLAS -PRICING OF PREVIOUSLY ANNOUNCED OFFERING OF 4.6 MILLION COMMON SHARES & ACCOMPANYING WARRANTS EACH AT $5.40 PER SHARE & ACCOMPANYING WARRANT Source text for Eikon: Further company coverage:

  20. Show article details.

    SELLAS Life Sciences Announces Pricing of $25.0 Million Underwritten Public Offering

    GlobeNewswire – 9:03 PM ET 03/31/2022

    SELLAS Life Sciences Group, Inc. (SLS), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced the pricing of its previously announced underwritten public offering of 4,629,630 shares of its common stock and accompanying warrants to purchase up to 4,629,630 shares of common stock at a combined public offer...

Page:

Today's and Upcoming Events

  • Aug
    10

    SLS to announce Q2 earnings (Unconfirmed)

Past Events (last 90 days)

  • May
    12

    SLS announced Q1 earnings.

Data provided by Thomson Reuters © 2022

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.